ASP Isotopes appoints Robery Ainscow as interim CEO

ASP Isotopes (ASPI) announced that, effective October 1, 2025, Paul Mann, the founder, Chairman and CEO of ASP Isotopes, will become Executive Chairman of ASP Isotopes and will be taking a temporary leave of absence from his CEO duties for health reasons. In consultation with Mr. Mann, and effective October 1, 2025, ASP Isotopes’ Board of Directors appointed Robert Ainscow, the Company’s COO, to serve as Interim CEO, in addition to his current duties. In the Executive Chairman role, Mr. Mann has responsibility, working with the Interim CEO and the Board, for: the overall leadership and strategic direction of the Company; providing guidance and support to senior management of the Company; and the coordination of the activities of the Board. In the role of Interim CEO, Ainscow has the responsibility for managing the CEO’s direct reports and communications with the Company’s industry partners, shareholders and other important stakeholders, among other CEO duties. Mr. Mann underwent a planned orthopaedic surgery in the United States on September 19, 2025. While the procedure was successfully performed, the post-operative course was somewhat more complicated than initially anticipated. Although the course and timing of the recovery are not yet certain, Mr. Mann has been advised that his recovery could take several months, during which time he will be unable to travel. As part of the Company’s preparation for the public listing of QLE, effective October 1, 2025, Michael Cunniffe has been appointed as CFO of QLE. Immediately before joining QLE, Mr. Cunniffe was the Managing Director UK for Danforth Advisors.